| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Therapeutic Radiology [B. C. T., B. G. H., L. N., J. Y., P. A. H., A. A. G., P. M. G.] and Pathology [L. K., D. C.], Yale University School of Medicine, New Haven, Connecticut 06520-8040; Jefferson Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-5541 [J-L. B., R. B.]
The insulin-like growth factor-I receptor (IGF-IR) plays a critical role in cell growth regulation and transformation. The radiosensitivity of NIH 3T3 fibroblasts overexpressing either wild-type or mutant IGF-IR was examined. High levels of wild-type IGF-IR conferred radioresistance, and mutational analysis revealed that this effect correlated with the transforming capacity but not the mitogenic activity of the receptor. The radioresistant phenotype was reversed when the cells were incubated with antisense oligonucleotides targeted to IGF-IR mRNA, demonstrating that IGF-IR directly influences radioresistance. The clinical significance of these findings was examined in an immunohistochemical analysis of primary breast tumors, revealing that high levels of IGF-IR in tumor samples were highly correlated with ipsilateral breast tumor recurrence (IBTR) following lumpectomy and radiation therapy (P = 0.001). Subgroup analysis revealed that, for early breast tumor relapses (within 4 years of initial breast tumor diagnosis), elevated levels of IGF-IR were strongly associated with IBTR (P = 0.004) but IGF-IR expression was not prognostic for IBTR from breast cancer patients with late relapses (P was not significant). These studies provide evidence for the influence of IGF-IR on cellular radioresistance and response to therapy and raise the possibility that the radiocurability of selected tumors may be improved by pharmaceutical strategies directed toward the IGF-IR.
1 This work was supported by the Yale University Department of Therapeutic Radiology, the Charles E. Culpeper Foundation, and NIH Grant ES05775.
2 To whom requests for reprints should be addressed, at the Department of Therapeutic Radiology, Yale University School of Medicine, P. O. Box. 208040, New Haven, CT 06520-8040. Phone: (203) 737-2788; Fax: (203) 737-2630; E-mail: peter.glazer@qm.yale.edu.
Received 5/ 5/97. Accepted 6/10/97.
This article has been cited by other articles:
![]() |
R. A. Jones, C. I. Campbell, J. J. Petrik, and R. A. Moorehead Characterization of a Novel Primary Mammary Tumor Cell Line Reveals that Cyclin D1 Is Regulated by the Type I Insulin-Like Growth Factor Receptor Mol. Cancer Res., May 1, 2008; 6(5): 819 - 828. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sisci, C. Morelli, C. Garofalo, F. Romeo, L. Morabito, F. Casaburi, E. Middea, S. Cascio, E. Brunelli, S. Ando, et al. Expression of nuclear insulin receptor substrate 1 in breast cancer J. Clin. Pathol., June 1, 2007; 60(6): 633 - 641. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Imsumran, Y. Adachi, H. Yamamoto, R. Li, Y. Wang, Y. Min, W. Piao, K. Nosho, Y. Arimura, Y. Shinomura, et al. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma Carcinogenesis, May 1, 2007; 28(5): 947 - 956. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P.V. Shekhar, S. Santner, K. A. Carolin, and L. Tait Direct Involvement of Breast Tumor Fibroblasts in the Modulation of Tamoxifen Sensitivity Am. J. Pathol., May 1, 2007; 170(5): 1546 - 1560. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-J. Liu, T. LaFortune, T. Honda, O. Ohmori, S. Hatakeyama, T. Meyer, D. Jackson, J. de Groot, and W.K. A. Yung Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo Mol. Cancer Ther., April 1, 2007; 6(4): 1357 - 1367. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L Henriksen, B. B Rasmussen, A. E Lykkesfeldt, S. Moller, B. Ejlertsen, and H. T Mouridsen Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays J. Clin. Pathol., April 1, 2007; 60(4): 397 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Allen, C. Saba, E. A. Armstrong, S.-M. Huang, S. Benavente, D. L. Ludwig, D. J. Hicklin, and P. M. Harari Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation Cancer Res., February 1, 2007; 67(3): 1155 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. R Hutcheson, J. M Knowlden, H. E Jones, R. S Burmi, R. A McClelland, D. Barrow, J. M W Gee, and R. I Nicholson Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S89 - S97. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cappuzzo, L. Toschi, G. Tallini, G. L. Ceresoli, I. Domenichini, S. Bartolini, G. Finocchiaro, E. Magrini, G. Metro, A. Cancellieri, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib Ann. Onc., July 1, 2006; 17(7): 1120 - 1127. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. W. Gee, and R. I. Nicholson Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor Endocrinology, November 1, 2005; 146(11): 4609 - 4618. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Reizner, S. Maor, R. Sarfstein, S. Abramovitch, W. V Welshons, E. M Curran, A. V Lee, and H. Werner The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-{alpha} and regulates IGF-I receptor gene transcription in breast cancer cells J. Mol. Endocrinol., August 1, 2005; 35(1): 135 - 144. [Abstract] [Full Text] [PDF] |
||||
![]() |
J M Gee, J F Robertson, E Gutteridge, I O Ellis, S E Pinder, M Rubini, and R I Nicholson Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S99 - S111. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Lu, H. Zhang, H. Koo, J. Tonra, P. Balderes, M. Prewett, E. Corcoran, V. Mangalampalli, R. Bassi, D. Anselma, et al. A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity J. Biol. Chem., May 20, 2005; 280(20): 19665 - 19672. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ahlen, J. Wejde, O. Brosjo, A. von Rosen, W.-H. Weng, L. Girnita, O. Larsson, and C. Larsson Insulin-Like Growth Factor Type 1 Receptor Expression Correlates to Good Prognosis in Highly Malignant Soft Tissue Sarcoma Clin. Cancer Res., January 1, 2005; 11(1): 206 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
H E Jones, L Goddard, J M W Gee, S Hiscox, M Rubini, D Barrow, J M Knowlden, S Williams, A E Wakeling, and R I Nicholson Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr. Relat. Cancer, December 1, 2004; 11(4): 793 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Shahrabani-Gargir, T. K. Pandita, and H. Werner Ataxia-Telangiectasia Mutated Gene Controls Insulin-Like Growth Factor I Receptor Gene Expression in a Deoxyribonucleic Acid Damage Response Pathway via Mechanisms Involving Zinc-Finger Transcription Factors Sp1 and WT1 Endocrinology, December 1, 2004; 145(12): 5679 - 5687. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Nagle, Z. Ma, M. A. Byrne, M. F. White, and L. M. Shaw Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis Mol. Cell. Biol., November 15, 2004; 24(22): 9726 - 9735. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-F. Chen and M.-S. Wong Genistein Enhances Insulin-Like Growth Factor Signaling Pathway in Human Breast Cancer (MCF-7) Cells J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2351 - 2359. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sachdev, J. S. Hartell, A. V. Lee, X. Zhang, and D. Yee A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells J. Biol. Chem., February 6, 2004; 279(6): 5017 - 5024. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Lu, H. Zhang, D. Ludwig, A. Persaud, X. Jimenez, D. Burtrum, P. Balderes, M. Liu, P. Bohlen, L. Witte, et al. Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody J. Biol. Chem., January 23, 2004; 279(4): 2856 - 2865. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Nicholson, I. R. Hutcheson, J. M. Knowlden, H. E. Jones, M. E. Harper, N. Jordan, S. E. Hiscox, D. Barrow, and J. M. W. Gee Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination Clin. Cancer Res., January 1, 2004; 10(1): 346S - 354S. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Burtrum, Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al. A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo Cancer Res., December 15, 2003; 63(24): 8912 - 8921. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Trojanek, T. Ho, L. Del Valle, M. Nowicki, J. Y. Wang, A. Lassak, F. Peruzzi, K. Khalili, T. Skorski, and K. Reiss Role of the Insulin-Like Growth Factor I/Insulin Receptor Substrate 1 Axis in Rad51 Trafficking and DNA Repair by Homologous Recombination Mol. Cell. Biol., November 1, 2003; 23(21): 7510 - 7524. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. S. Kang, A. Urbonas, A. Baddoo, S. Baskin, A. Malhotra, and L. G. Meggs IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose Am J Physiol Renal Physiol, November 1, 2003; 285(5): F1013 - F1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yu, H. Watanabe, H. Shibuya, and M. Miura Redundancy of Radioresistant Signaling Pathways Originating from Insulin-like Growth Factor I Receptor J. Biol. Chem., February 21, 2003; 278(9): 6702 - 6709. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sachdev, S.-L. Li, J. S. Hartell, Y. Fujita-Yamaguchi, J. S. Miller, and D. Yee A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I Cancer Res., February 1, 2003; 63(3): 627 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Zellweger, K. Chi, H. Miyake, H. Adomat, S. Kiyama, K. Skov, and M. E. Gleave Enhanced Radiation Sensitivity in Prostate Cancer by Inhibition of the Cell Survival Protein Clusterin Clin. Cancer Res., October 1, 2002; 8(10): 3276 - 3284. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Turner, M. Ottey, D. B. Zimonjic, M. Potoczek, W. W. Hauck, E. Pequignot, C. L. Keck-Waggoner, C. Sevignani, C. M. Aldaz, P. A. McCue, et al. The Fragile Histidine Triad/Common Chromosome Fragile Site 3B Locus and Repair-deficient Cancers Cancer Res., July 15, 2002; 62(14): 4054 - 4060. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. O. Hellawell, G. D. H. Turner, D. R. Davies, R. Poulsom, S. F. Brewster, and V. M. Macaulay Expression of the Type 1 Insulin-like Growth Factor Receptor Is Up-Regulated in Primary Prostate Cancer and Commonly Persists in Metastatic Disease Cancer Res., May 1, 2002; 62(10): 2942 - 2950. [Abstract] [Full Text] [PDF] |
||||
![]() |
C L Chernicky, H Tan, L Yi, J R L. de Mola, and J Ilan Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo Mol. Pathol., April 1, 2002; 55(2): 102 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tezuka, H. Watanabe, S. Nakamura, D. Yu, W. Aung, T. Sasaki, H. Shibuya, and M. Miura Antiapoptotic Activity Is Dispensable for Insulin-like Growth Factor I Receptor-mediated Clonogenic Radioresistance after {gamma}-Irradiation Clin. Cancer Res., October 1, 2001; 7(10): 3206 - 3214. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bartucci, C. Morelli, L. Mauro, S. Ando', and E. Surmacz Differential Insulin-like Growth Factor I Receptor Signaling and Function in Estrogen Receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 Breast Cancer Cells Cancer Res., September 1, 2001; 61(18): 6747 - 6754. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Shaw Identification of Insulin Receptor Substrate 1 (IRS-1) and IRS-2 as Signaling Intermediates in the {alpha}6{beta}4 Integrin-Dependent Activation of Phosphoinositide 3-OH Kinase and Promotion of Invasion Mol. Cell. Biol., August 1, 2001; 21(15): 5082 - 5093. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Benini, M. C. Manara, N. Baldini, V. Cerisano, Massimo Serra, M. Mercuri, P.-L. Lollini, P. Nanni, P. Picci, and K. Scotlandi Inhibition of Insulin-like Growth Factor I Receptor Increases the Antitumor Activity of Doxorubicin and Vincristine against Ewing's Sarcoma Cells Clin. Cancer Res., June 1, 2001; 7(6): 1790 - 1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Andrews, M. Resnicoff, A. E. Flanders, L. Kenyon, M. Curtis, G. Merli, R. Baserga, G. Iliakis, and R. D. Aiken Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas J. Clin. Oncol., April 15, 2001; 19(8): 2189 - 2200. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Turner, S. Krajewski, M. Krajewska, S. Takayama, A. A. Gumbs, D. Carter, T. R. Rebbeck, B. G. Haffty, and J. C. Reed BAG-1: A Novel Biomarker Predicting Long-Term Survival in Early-Stage Breast Cancer J. Clin. Oncol., February 15, 2001; 19(4): 992 - 1000. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Dunn, J. V. Torres, J. S. Oh, D. M. Cykert, and J. C. Barrett Up-Regulation of Urokinase-Type Plasminogen Activator by Insulin-like Growth Factor-I Depends upon Phosphatidylinositol-3 Kinase and Mitogen-activated Protein Kinase Kinase Cancer Res., February 1, 2001; 61(4): 1367 - 1374. [Abstract] [Full Text] |
||||
![]() |
U. Hermanto, C. S. Zong, and L.-H. Wang Inhibition of Mitogen-activated Protein Kinase Kinase Selectively Inhibits Cell Proliferation in Human Breast Cancer Cells Displaying Enhanced Insulin-like Growth Factor I-mediated Mitogen-activated Protein Kinase Activation Cell Growth Differ., December 1, 2000; 11(12): 655 - 664. [Abstract] [Full Text] |
||||
![]() |
H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Lehman, B. G. Haffty, C. J. Carbone, L. R. Bishop, A. A. Gumbs, S. Krishnan, P. G. Shields, R. Modali, and B. C. Turner Elevated Frequency and Functional Activity of a Specific Germ-Line p53 Intron Mutation in Familial Breast Cancer Cancer Res., February 1, 2000; 60(4): 1062 - 1069. [Abstract] [Full Text] |
||||
![]() |
B. C. Turner, E. Harrold, E. Matloff, T. Smith, A. A. Gumbs, M. Beinfield, B. Ward, M. Skolnick, P. M. Glazer, A. Thomas, et al. BRCA1/BRCA2 Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With BRCA1/BRCA2 Mutations J. Clin. Oncol., October 1, 1999; 17(10): 3017 - 3024. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Peruzzi, M. Prisco, M. Dews, P. Salomoni, E. Grassilli, G. Romano, B. Calabretta, and R. Baserga Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis Mol. Cell. Biol., October 1, 1999; 19(10): 7203 - 7215. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xie, B. Skytting, G. Nilsson, B. Brodin, and O. Larsson Expression of Insulin-like Growth Factor-1 Receptor in Synovial Sarcoma: Association with an Aggressive Phenotype Cancer Res., August 1, 1999; 59(15): 3588 - 3591. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Peretz, R. Jensen, R. Baserga, and P. M. Glazer ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response PNAS, February 13, 2001; 98(4): 1676 - 1681. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |